Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03506477|
Recruitment Status : Completed
First Posted : April 24, 2018
Results First Posted : January 20, 2021
Last Update Posted : January 20, 2021
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Plaque Psoriasis Psoriasis||Drug: Enstilar® foam Drug: Vehicle foam||Phase 4|
Psoriasis is a chronic inflammatory disorder primarily affecting the skin and joints. This condition occurs in different ethnic groups worldwide with varying prevalence.
There are notable differences in psoriasis presentation in skin of color groups. Black patients with psoriasis tend to have less erythema, increased risk of pigmentation, thicker plaques, more scaling, and greater body involvement as compared to white patients. The resolution of psoriasis lesions in darker skin types is associated with a higher rate of dyspigmentation (both hyper- and hypo-pigmentation), which may be more bothersome to patients than the psoriasis itself. Further, several studies have shown that psoriasis is associated with greater psychological impact and worse quality of life in non-whites with psoriasis compared to whites.
Unique issues in skin of color populations make studies dedicated to darker skin types essential for the treatment of psoriasis in these populations. This study will evaluate the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in darker skin types. This study will also evaluate the degree of erythema versus hyperpigmentation in psoriasis plaques as well as the effect of Enstilar ® on post-inflammatory hyperpigmentation and quality of life in skin of color.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||4:1 Enstilar(R): placebo from baseline to week 4, then open-label Enstilar from weeks 4 to 8.|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Double-blind, vehicle-controlled from week 0 to 4|
|Official Title:||A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color|
|Actual Study Start Date :||May 21, 2018|
|Actual Primary Completion Date :||September 25, 2019|
|Actual Study Completion Date :||September 25, 2019|
Experimental: Enstilar® foam
Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
Drug: Enstilar® foam
for 4 weeks
Other Name: Enstilar 0.005%-0.064% Topical Foam
Placebo Comparator: Vehicle foam
does not contain the active ingredient
Drug: Vehicle foam
for 4 weeks
- Number of Patients Who Achieved Treatment Success [ Time Frame: Week 4 ]Number of patients at week 4 who achieved treatment success according to Investigator's Global Assessment (IGA mod 2011) of the entire body including scalp. IGA ranges from 0 (clear) to 4 (severe). Treatment success is defined as IGA of clear (0) or almost clear (1) for patients with ≥ moderate disease at baseline or IGA of clear (0) for patients with mild disease at baseline.
- Number of Participants With Achieving Targeted Psoriasis Area and Severity Index (PASI) [ Time Frame: 4 weeks, 8 weeks ]Number of patients achieving ≥50% improvement and/or ≥75% improvement in PASI at weeks 4 and 8 . PASI combines the assessment of the severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease)
- Number of Patients Achieving Targeted Psoriasis Scalp Severity Index (PSSI) [ Time Frame: 2 weeks, 4 weeks, 8 weeks ]Number of patients achieving ≥50% improvement and/or ≥75% improvement in PSSI at weeks 2, 4 and 8. The Psoriasis Scalp Severity Index (PSSI) assesses severity of scalp disease along the parameters of erythema, induration, and desquamation. The PSSI uses a 5-point scale to grade the three aforementioned clinical parameters. The parameters scores are summed and multiplied by an integer (0-6) that represents the area of affected scalp. The PSSI score ranges from 0 (no disease) to 72 (maximal disease).
- Number of Patients With Treatment Success According to Investigator Global Assessment (IGA Mod 2011) [ Time Frame: at week 8 ]Number of patients at week 8 who achieved treatment success according to IGA mod 2011 of the entire body including scalp. IGA ranges from 0 (clear) to 4 (severe). Treatment success is defined as IGA of clear (0) or almost clear (1) for patients with ≥ moderate disease at baseline or IGA of clear (0) for patients with mild disease at baseline.
- Number of Participants Who Achieved Treatment Success According to Scalp Investigator Global Assessment (ScIGA) [ Time Frame: 4 weeks, 8 weeks ]Number of patients at weeks 4 and 8 who achieved treatment success according to ScIGA. ScIGA ranges from 0 (clear) to 4 (severe). Treatment success is defined as ScIGA of clear (0) or almost clear (1) for patients with ≥ moderate disease at baseline or ScIGA of clear (0) for patients with mild disease at baseline.
- Patient's Global Assessment of Itch [ Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks ]Patient's Global Assessment of Itch as compared to baseline measured by Visual Analog Scale (VAS). The VAS is a numerical scale used to assess patients' perception of pruritus/itch.The evaluation is a 10cm long line on which the subjects indicate the severity of their pruritus from "0" (no pruritus) to "10" (severe pruritus).
- Number of Participants Who Clear or Almost Clear Disease According to the Patient's Global Assessment of Disease Severity (PaGA) [ Time Frame: 4 weeks, 8 weeks ]PaGA have 5 distinct options ranging from (0) "Clear" to (4) "Severe." Number of participants with treatment response defined as clear or almost clear disease (for those with moderate or severe disease at baseline) or clear disease (for those with mild disease at baseline) at 4 weeks and 8 weeks.
- Erythema Indices of Target Psoriasis Plaque [ Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks ]A skin spectrophotometer (Mexameter) was used to quantify the degree of erythema of lesional skin compared to an index area (of unaffected skin). The mexameter measures from 0-999. The higher the value for erythema index the more red pigmentation in the skin, this is assessed by quantification of hemoglobin in the skin via reflectance spectroscopy.
- Melanin Indices of Target Psoriasis Plaque [ Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks ]A skin spectrophotometer (Mexameter) was used to quantify the melanin index (degree of hyperpigmentation or hypopigmentation) of lesional skin compared to an index area of unaffected skin. The mexameter measures from 0-999. The higher the value for melanin index, the more brown pigment in the skin, this is assessed by quantification of melanin in the skin via reflectance spectroscopy.
- Physician Dyspigmentation Visual Analog Scale (VAS) [ Time Frame: baseline, 4 weeks, 8 weeks ]An investigator performed a visual analog scale (VAS) rating the degree of dyspigmentation of the skin. This VAS ranges from - 5 to 5 as follows: 5 severe dark brown pigmentation (darkest imaginable color), 4 dark brown pigmentation, 3 medium brown pigmentation, 2 light brown pigmentation, 1 slight dark pigmentation (barely perceptible compared to surrounding skin), 0 baseline skin pigmentation, -1 slight hypopigmentation (barely perceptible compared to surrounding skin), -2 mild hypopigmentation (light brown), -3 moderate hypopigmentation (creme-colored skin), -4 severe hypopigmentation (almost complete absence of pigment), -5 depigmentation (complete absence of pigment).
- Mean Change in Dermatology Life Quality Index (DLQI) [ Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks ]DLQI full scale ranges from 0 (no effect at all on patient's life) to 30 (extremely large effect on patients' life). Mean change from Baseline in DLQI at 2, 4, and 8 weeks.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Provide written, signed and dated informed consent prior to initiating any study-related activities.
- Male or female >18 years of age at the time of screening
- Fitzpatrick Skin phototype IV-VI, non-white race/ethnicity, including but not limited to - --African Americans, Asians, Pacific Islanders and Hispanics.
- Clinical diagnosis of chronic plaque-type psoriasis of the body
- Plaque psoriasis with ≥2% Body Surface Area (BSA) involvement (may include scalp involvement), PASI Score ≥ 2, IGA mod 2011 score of 2 or greater (based on scale of 0-4)
- Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While using investigational product and for at least 28 days after last application of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options d
- Must be in general good health as judged by the Investigator, based on medical history and physical examination.
- Form of diagnosed psoriasis other than chronic plaque psoriasis (i.e. guttate, erythrodermic, pustular)
- Diagnosis of other active, ongoing skin diseases or skin infections that may interfere with examination of psoriasis lesions
- Ongoing use of other psoriasis treatment including but not limited to topical or systemic corticosteroids, other topical medications (i.e. coal tar), oral or biologic medications for the treatment of psoriasis, and UV therapy. The following washout periods will be required: 2 weeks for topical therapy; 2 weeks for phototherapy; 12 weeks for biologic or targeted therapies; 4 weeks for other systemic therapies
- Use of oral estrogen therapy, excluding oral contraceptive pills
- Women who are pregnant, nursing, or of child-bearing potential who are unwilling to use appropriate method(s) of contraception.
- Patients unwilling to limit exposure to UV light
- Current significant medical problems that, in the discretion of the investigator, would put the patient at significant risk
- Patients with disorders of calcium metabolism and/or hypercalcemia
- Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer)
- History of allergy to any component of the IP
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03506477
|United States, New York|
|Mount Sinai West|
|New York, New York, United States, 10023|
|Principal Investigator:||Andrew Alexis, MD, MPH||Icahn School of Medicine at Mount Sinai|
Documents provided by Andrew Alexis, MD, Icahn School of Medicine at Mount Sinai:
|Responsible Party:||Andrew Alexis, MD, Chair, Department of Dermatology, Icahn School of Medicine at Mount Sinai|
|Other Study ID Numbers:||
HSM# 17-05032 ( Other Identifier: Icahn School of Medicine at Mount Sinai )
|First Posted:||April 24, 2018 Key Record Dates|
|Results First Posted:||January 20, 2021|
|Last Update Posted:||January 20, 2021|
|Last Verified:||September 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||With Leo, Pharma.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||Yes|
skin of color
Skin Diseases, Papulosquamous